HR 6930

MADE in America Act of 2020

Congress: 116 (2019–2021, Ended)
Chamber: House
Policy Area: Health
Introduced: May 19, 2020
Current Status: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means
Latest Action: Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (May 19, 2020)
Official Text: https://www.congress.gov/bill/116th-congress/house-bill/6930

Sponsor

Name: Rep. Carter, Earl L. "Buddy" [R-GA-1]
Party: Republican • **State:** GA • **Chamber:** House

Cosponsors (8 total)

Cosponsor	Party / State	Role	Date Joined
Rep. Crawford, Eric A. "Rick" [R-AR-1]	R · AR		May 19, 2020
Rep. Griffith, H. Morgan [R-VA-9]	R · VA		May 19, 2020
Rep. McKinley, David B. [R-WV-1]	R · WV		May 19, 2020
Rep. Soto, Darren [D-FL-9]	D · FL		May 19, 2020
Rep. Van Drew, Jefferson [R-NJ-2]	R · NJ		Jun 18, 2020
Rep. Westerman, Bruce [R-AR-4]	R · AR		Jun 18, 2020
Rep. Cartwright, Matt [D-PA-8]	D · PA		Jul 9, 2020
Rep. Rice, Tom [R-SC-7]	R · SC		Oct 1, 2020

Committee Activity

Committee	Chamber	Activity	Date
Energy and Commerce Committee	House	Referred To	May 19, 2020
Ways and Means Committee	House	Referred To	May 19, 2020

Subjects & Policy Tags

Policy Area:

Health

Related Bills

No related bills are listed.

Summary (as of May 19, 2020)

Manufacturing API, Drugs, and Excipients in America Act of 2020 or the MADE in America Act of 2020

This bill establishes a tax credit for taxpayers engaged in medical production activities in certain areas and contains other provisions related to pharmaceuticals.

An eligible taxpayer may claim a tax credit equal to 30% of qualified expenditures related to the production of pharmaceuticals, medical devices, or other related items in a designated qualified opportunity zone with a poverty rate higher than 30%.

In addition, the Food and Drug Administration shall continue a program to evaluate new drug manufacturing technologies included in an application for approval of a drug or biological product. The bill imposes various requirements on this program, including deadlines for evaluating such a technology.

Furthermore, the Department of Health and Human Services shall establish or expand programs to promote regulatory consistency and cooperation with drug regulatory authorities in other countries.

Actions Timeline

- **May 19, 2020:** Introduced in House
- **May 19, 2020:** Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.